TipRanks
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
US Market
Want to see AUPH full AI Analyst Report?

Aurinia Pharmaceuticals (AUPH) Revenue by Segment

2,170 Followers

Revenue by Segment

Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This helps assess the company's strategic focus and potential areas of risk or opportunity.
Net Product Sales have become the primary, steadily compounding revenue engine—evidence of successful commercialization and market uptake—while License/Collaboration/Royalty remains episodic, producing large one‑off spikes that distort headline growth. The multi‑year acceleration into high‑tens of millions per quarter shifts Aurinia from milestone‑dependent to product‑driven; the modest Q1 2026 pullback looks like timing or seasonality rather than structural weakness, so investors should model future revenue around product momentum and treat license income as unpredictable upside.
Date
Net Product Sales
License, Collaboration and Royalty
Jun 30, 2026
$79.41M$3.81M
Mar 31, 2026
$73.56M$4.14M
Dec 31, 2025
$74.17M$2.94M
Sep 30, 2025
$70.63M$2.84M
Jun 30, 2025
$66.57M$3.43M
Mar 31, 2025
$59.97M$2.49M
Dec 31, 2024
$57.58M$2.29M
Sep 30, 2024
$55.50M$12.27M
Jun 30, 2024
$55.03M$2.16M
Mar 31, 2024
$48.07M$2.23M